Measuring real-time PK/PD by monitoring aberrant chaperone activity

Measuring PK/PD in real time by selectively targeting protein networks

A Memorial Sloan Kettering Cancer Center team developed an imaging probe for aberrant protein networks that could guide more optimal drug dosing and scheduling earlier in development.

In cancer, tumor biopsy collection as well as heterogeneity within tumors and among patients present logistical and

Read the full 439 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE